Durvalumab et tremelimumab en association à la chimiothérapie en première ligne du cancer bronchopulmonaire non à petites cellules (CBNPC) métastatique sans addiction oncogénique
- 25 September 2023
- journal article
- editorial
- Published by Elsevier in Bulletin du Cancer
- Vol. 110 (11) , 1094-1096
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON StudyJournal of Clinical Oncology, 2023
- Nouvelles AMMs : ipilimumab-nivolumab en association à la chimiothérapie en première ligne dans le cancer bronchique non à petites cellules métastatiquesBulletin du Cancer, 2021
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018